Zai Lab Limited (ZLAB)

NASDAQ: ZLAB · IEX Real-Time Price · USD
42.82
-0.36 (-0.83%)
Aug 19, 2022 4:30 PM EDT - Market closed
-0.83%
Market Cap 4.19B
Revenue (ttm) 182.17M
Net Income (ttm) -528.56M
Shares Out 97.91M
EPS (ttm) -5.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 146,526
Open 42.09
Previous Close 43.18
Day's Range 41.25 - 43.13
52-Week Range 22.51 - 152.82
Beta 1.06
Analysts Buy
Price Target 82.98 (+93.8%)
Earnings Date Aug 9, 2022

About ZLAB

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular ... [Read more...]

Industry Biotechnology
IPO Date Sep 20, 2017
Employees 1,951
Stock Exchange NASDAQ
Ticker Symbol ZLAB
Full Company Profile

Financial Performance

In 2021, Zai Lab's revenue was $144.31 million, an increase of 194.77% compared to the previous year's $48.96 million. Losses were -$704.47 million, 162.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for ZLAB stock is "Buy." The 12-month stock price forecast is 82.98, which is an increase of 93.79% from the latest price.

Price Target
$82.98
(93.79% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Earnings Season Could Be Great for Zai Lab (ZLAB)

Zai Lab (ZLAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p

Wall Street Analysts Think Zai Lab Limited Unsponsored ADR (ZLAB) Could Surge 145%: Read This Before Placing a Bet

The mean of analysts' price targets for Zai Lab Limited Unsponsored ADR (ZLAB) points to a 144.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong a...

Qiming's Portfolio Company InventisBio Lists on STAR Market

SHANGHAI , July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technolo...

Other symbols: BILISDGRZH

Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022

Company to Host Conference Call and Webcast on August 10, 2022, at 8:00 a.m. ET Company to Host Conference Call and Webcast on August 10, 2022, at 8:00 a.m. ET

Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., July 17, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical com...

Zai Lab Announces Acceptance by China's NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis

Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist for gMG patients in China Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist fo...

Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited

–   First company to Convert from Secondary to Primary Listing Status in Hong Kong

Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

-- Breakthrough Therapy Designations granted for ROS1-positive non-small cell lung cancer (NSCLC) patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor (TKI) with or without prior ch...

Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Ca...

Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy

Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical co...

Zai Lab Announces Upcoming Presentations at June Investor Conferences

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical co...

Zai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical co...

Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates

Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET

Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adu...

- Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardless ...

Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Pos...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass. and SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Zai Lab (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceu...

Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company's Independent Registered Public Accounting Firm

Zai Lab's engagement of an audit firm located in the United States is expected to facilitate the Company's continued listing on Nasdaq because KPMG is subject to inspection by the PCAOB Zai Lab's engage...

Zai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022

-- Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET -- Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securiti...

NEW YORK , April 18, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Zai Lab Limited (NASDA...

ZLAB Investor Notice: ROSEN, A Leading Law Firm, Encourages Zai Lab Limited Investors with Losses to Inquire About Se...

New York, New York--(Newsfile Corp. - April 7, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai ...

Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting

-  First preview of preclinical data for ZL-1218, an anti-CCR8 antibody, in an oral presentation

ZLAB INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About ...

NEW YORK , April 4, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (N...

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact t...

LOS ANGELES--(BUSINESS WIRE)---- $ZLAB #ZLAB--The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting sta...

Other symbols: BGNECASIHCM

EQUITY ALERT: Rosen Law Firm Encourages Zai Lab Limited Investors with Losses in Excess of $100K to Inquire About Sec...

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) r...